title: National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.
abstract: Various organizations and agencies have issued recommendations for the management of dyslipidemia. Although many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) atherosclerotic cardiovascular disease risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol-non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol-as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia.
authors.affiliation: Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: tjaco02@emory.edu.
authors.forename: Terry A
authors.initials: TA
authors.lastname: Jacobson
authors.affiliation: Oregon State University/Oregon Health & Science University, College of Pharmacy, Portland, OR, USA.
authors.forename: Matthew K
authors.initials: MK
authors.lastname: Ito
authors.affiliation: Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL, USA.
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Maki
authors.affiliation: University of Miami Health System, Miami, FL, USA.
authors.forename: Carl E
authors.initials: CE
authors.lastname: Orringer
authors.affiliation: Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA.
authors.forename: Harold E
authors.initials: HE
authors.lastname: Bays
authors.affiliation: Baylor College of Medicine, Houston, TX, USA.
authors.forename: Peter H
authors.initials: PH
authors.lastname: Jones
authors.affiliation: Virginia Commonwealth University and National Clinical Research, Richmond, VA, USA.
authors.forename: James M
authors.initials: JM
authors.lastname: McKenney
authors.affiliation: The University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Scott M
authors.initials: SM
authors.lastname: Grundy
authors.affiliation: University of Washington/Harborview Medical Center, Seattle, WA, USA.
authors.forename: Edward A
authors.initials: EA
authors.lastname: Gill
authors.affiliation: Oklahoma University Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Wild
authors.affiliation: Cook Children's Medical Center, Fort Worth, TX, USA.
authors.forename: Don P
authors.initials: DP
authors.lastname: Wilson
authors.affiliation: Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: W Virgil
authors.initials: WV
authors.lastname: Brown
mesh_terms: D000328:Adult; D018450:Disease Progression; D050171:Dyslipidemias / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy*; D006040:Goals; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D008019:Life Style; D008074:Lipoproteins / Q000378:metabolism; D018570:Risk Assessment; D012955:Societies, Medical
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins
keywords: Atherogenic cholesterol; Atherosclerotic cardiovascular disease; Clinical recommendations; Coronary heart disease; Dyslipidemia; Lipoproteins; Low-density lipoprotein cholesterol